Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1800 OWENS STREET, SUITE 900 SAN FRANCISCO CA 94158 |
Tel: | N/A |
Website: | https://www.vir.bio |
IR: | See website |
Key People | ||
Marianne De Backer Chief Executive Officer, Director | Sung H. Lee Chief Financial Officer, Executive Vice President | Ann M. Hanly Executive Vice President, Chief Technology Officer |
Steven Rice Executive Vice President, Chief Administrative Officer | Jennifer Towne Executive Vice President, Chief Scientific Officer | Jeff Calcagno Executive Vice President and Chief Business Officer |
Sasha Damouni Ellis Executive Vice President and Chief Corporate Affairs Officer | Phil Pang Executive Vice President, Chief Medical Officer, Interim Head of Research |
Business Overview |
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle. |
Financial Overview |
For the fiscal year ended 31 December 2023, Vir Biotechnology Inc revenues decreased 95% to $86.2M. Net loss totaled $615.1M vs. income of $515.8M. Revenues reflect Collaboration revenue decrease of 98% to $37.3M, Contract revenue decrease of 96% to $2.2M, License revenue from a related party decrease from $22.3M to $0K. Net loss reflects Research and development increase of 25% to $526.4M (expense). |
Employees: | 587 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $86.18M as of Dec 31, 2023 |
EBITDA (TTM): | -$651.85M as of Dec 31, 2023 |
Net annual income (TTM): | -$615.06M as of Dec 31, 2023 |
Free cash flow (TTM): | -$800.36M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 135,032,268 as of Feb 16, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |